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Claudio AnasettiUnrelated donors are more commonly used than
siblings for allogenic stem cell transplantation. How-
ever, despite almost 20 million donors and cords avail-
able worldwide, only two-thirds of the white
population, and less of smaller ethnic minorities, can
find a donor fully compatible for HLA-A, -B, -C,
and -DRB1 loci, — such is the enormous population
diversity at these loci. For the patients without such
a match, clinicians struggle to pick the best possible
donor among those who are mismatched. In this issue,
Spellman et al. [1] evaluated an algorithm established
by Elsner et al. [2] to estimate the allogenic reaction
potential betweenmismatched individuals. TheHisto-
Check program is available online at http://www.his-
tocheck.de and can be used by anyone to calculate
a dissimilarity score between two individuals mis-
matched for one HLA molecule [3]. The analysis
used the National Marrow Donor Program transplan-
tation outcome database previously reported by Lee
et al. [4], and single locus mismatched pairs were
scored by the HistoCheck algorithm. With the excep-
tion of neutrophil engraftment in a subset analysis, no
association was found between the dissimilarity score
and transplantation outcome. What is the lesson
from this study? The principles used to calculate the
dissimilarity score seem sound: the first is the func-
tional relevance of mismatched amino acid residues
within the HLA molecule. Amino acids that anchor
the antigenic peptide or bind to the T cell antigen re-
ceptor score higher than others. The second principle
assumes that disparities between amino acids that are
structurally ‘‘similar,’’ as defined by Risler et al. [5],
are better tolerated immunologically than dissimilar
ones. By the Risler criteria, tyrosine and phenylalanine
that differ only for a hydroxylic group have a score of 4
(similar), whereas tyrosine and serine that differ for anDepartment of Blood and Marrow Transplantation,
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100 (less similar). The message of this article is that
the ‘‘similarity’’ between the mismatched amino acids
is not good for the patients after all. Other groups
have investigated how to seek out ‘‘permissive’’ mis-
matches, and the greatest advance in the field has
been made by Kawase, Morishima, and collaborators
from the Japan National Donor Program (JMDP)
[6-8]. Subsequent work fromMarino et al. [9] is largely
confirmatory of the main JMDP findings using a pre-
dominantly white population for study. Through a se-
ries of publications, the Japanese investigators
provided convincing data that mismatch for certain
specific amino acids in positions that function as pep-
tide binding residues at HLA-A and -C, and killer
cell immunoglobulin-like receptor (KIR) binding res-
idues at HLA-C are responsible for graft rejection,
graft-versus-host disease (GVHD), prevention of leu-
kemia relapse, and, overall mortality. The Japanese
data are consistent with the principle adopted by
Elsner that amino acid disparities for antigenic peptide
binding sites in the HLA molecule can be the cause of
alloreactivity, however, do not support a significant
role for TCR binding sites and extend prior data
from related mismatched transplantations on the rele-
vance of KIR binding sites. As understanding the rela-
tionship between HLA structure and function evolves,
it is likely that additional HLA polymorphisms will
gain relevance in transplantation. Doubts were raised
against the Elsner assumption that disparity for similar
amino acids has less relevance to alloreactivity. In the
studies by the JMDP, mismatches for tyrosine versus
phenylalanine in position 9 of HLA-A or position 99
of HLA-C (classified similar by the HistoCheck with
a score of 4) were associated with a 1.7 hazard of severe
acute GVHD compared to match. Mismatch for tyro-
sine versus serine in position 9 of HLA-A (classified
less similar by HistoCheck with a score of 45) were
also associated with a 1.7 hazard of severe acute
GVHD. Asparagine and serine differ only slightly in
their side chain (HistoCheck score 7), however, such
disparity in position 77 at HLA-C, the KIR2DL bind-
ing site, was associated with graft rejection, GVHD,
and protection from leukemia relapse. These observa-
tions indicate that even subtle differences in the struc-
ture of donor and recipient HLA molecules at binding
sites for peptide, KIR ligands, and possibly TCR may
elicit alloreactivity.657
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If at once you don’t succeed, should we really try,
try again?
Sergio GiraltIn this edition of Biology of Blood and Marrow
Transplantation, Jimenez-Zepeda et al. [1] explore the
role of a second autologous stem cell transplant
(ASCT) as salvage therapy for patients with multiple
myeloma. Although all the pitfalls and caveats regard-
ing retrospective reviews apply to this analysis (ie, se-
lection bias, uncertain denominator, patient and
treatment heterogeneity, etc.), we can learn from this
17-year single institutional experience.
Salvage high-dose therapy with ASCT improved
responses to induction therapy in most patients.
Complete remission rates increased from 0% to
7.7%; very good partial response rates increased
from 12.5% to 39.7% with partial remission or
greater rates increasing from 86.2% to 97.4%. The
median time to relapse after transplant was 19
months, and treatment-related deaths occurred in2.6% of patients. As reported by others, remission du-
ration after the first autograft predicts response and
remission duration after a second autograft. Patients
relapsing within 24 months of their initial autograft
had a median progression-free survival of 9.8 months,
whereas patients whose remission duration lasted
more than 2 years had a progression-free survival of
17.3 months. Looking at these data, it is important
to note that these patients were selected based on
their response to re-induction therapy. In contrast,
more than 20 years ago, Jagannath et al. [2] reported
on 21 patients who were resistant to standard
melphalan-prednisone and vincristine, adriamycin,
dexamethasone and received high-dose therapy with
bone marrow support. Five toxic deaths occurred in
these patients with refractory relapsed myeloma and
the remission duration was approximately 7 months.
Thus, this strategy is not optimally effective in multi-
ply relapsed and refractory patients.
The report of Jimenez-Pineda et al. [1] confirms
previous reports of the use of high-dose therapy with
ASCT as consolidation therapy for patients relapsing
after primary therapy. Response rates of greater than
75% are routinely reported, but with few patients
achieving a complete remission. Remission durations
of 12 to 18 months are usually reported with a fraction
of patients having long-term disease control. In all re-
ports, chemosensitivity as well as duration of myeloma
